NICM
BPMC

Neo Ivy Capital Management’s Blueprint Medicines BPMC Stock Holding History

Neo Ivy Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,754
Closed -$509K – 366
2025
Q1 		$509K Buy
+5,754
New +$561K 0.16% 193
2023
Q3 		– Sell
-3,516
Closed -$222K – 333
2023
Q2 		$222K Buy
+3,516
New +$191K 0.12% 208
2022
Q4 		$222K Buy
5,070
+2,558
+102% +$123K 0.15% 219
2022
Q3 		$166K Buy
+2,512
New +$161K 0.44% 75
2021
Q1 		– Sell
-429
Closed -$48K – 482
2020
Q4 		$48K Buy
+429
New +$45.2K 0.05% 308
2019
Q3 		– Sell
-3
Closed – – 294
2019
Q2 		$0 Buy
+3
New +$248 ﹤0.01% 273

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Neo Ivy Capital Management's BPMC Position: Q2 2025 in Review

Neo Ivy Capital Management sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 5,754 shares — an estimated $509K sold.

Neo Ivy Capital Management first reported a position in BPMC in Q2 2019 and held it in 6 quarters. The position peaked at $509K in Q1 2025. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Neo Ivy Capital Management reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Neo Ivy Capital Management sold 5,754 Blueprint Medicines shares in Q2 2025, an estimated $509K.
  • Neo Ivy Capital Management first reported a position in Blueprint Medicines in Q2 2019 and held it in 6 quarters.
  • Neo Ivy Capital Management's Blueprint Medicines position peaked at $509K in Q1 2025.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Neo Ivy Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.